Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Giandomenico Roviello, Alberto D'Angelo, Raheleh Roudi, Roberto Petrioli, Enrico Mini

Research output: Contribution to journalReview article

2 Citations (Scopus)


Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.

Original languageEnglish
Article number5692317
Number of pages9
JournalJournal of oncology
Publication statusPublished - 4 Jul 2019

Cite this